AI Article Synopsis
- Studies are highlighting the need for better treatments for non-small cell lung cancer (NSCLC) patients with KRAS or BRAF mutations.
- Researchers tested the effects of paclitaxel and sorafenib alone and together on NSCLC cell lines, discovering that using paclitaxel followed by sorafenib produced a stronger antitumor response.
- The combination works by reducing levels of key proteins, indicating potential for further clinical trials to confirm its effectiveness.
Article Abstract
Studies on non-small cell lung cancer (NSCLC) patients with KRAS or BRAF mutations are urgently needed to improve clinical outcomes. We evaluated the cytotoxicities of paclitaxel and sorafenib alone and in combination in NSCLC cell lines with KRAS or BRAF mutations and investigated the mechanism of the interaction between the drugs. We found synergistic antitumor efficacy with paclitaxel followed by sorafenib in in vitro and in vivo models of NSCLC. And, we determined that downregulation of the phosphorylated ERK and Rb, and Mcl-1 plays a critical role in the synergistic activity of the drugs. Further clinical trials are needed to verify the antitumor efficacy of this combination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canlet.2012.03.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!